Fig. 2: ISG15 is upregulated in several types of cancer. | Experimental & Molecular Medicine

Fig. 2: ISG15 is upregulated in several types of cancer.

From: SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity

Fig. 2

a mRNA expression levels of ISG15 and SIRT1 in paired tumor and adjacent normal tissues of nine tumor types in The Cancer Genome Atlas (TCGA) database. The TCGA RNA-seq data were obtained from the Genomic Data Commons (GDC), and log2-transformed transcripts per million (TPM) values are shown. b Boxplot showing the distribution of ISG15 and SIRT1 mRNA expression levels in 1404 cancer cell lines across 28 cancer types. mRNA expression values are presented as log2-transformed TPM values determined by RNA-seq using a pseudocount of 1. c Distribution of ISG15 and SIRT1 protein expression levels quantified by mass spectrometry in 375 cancer cell lines across 21 cancer types. Protein expression values are presented in a log2-transformed, normalized format. Proteomic and RNA-seq datasets of the cancer cell lines in the CCLE were obtained from the DepMap portal (https://depmap.org/portal/). d A scatter plot illustrating the relationship between ISG15 and SIRT1 protein expression across 375 cancer cell lines (depicted as gray dots) and 60 non-small cell lung carcinoma (NSCLC) cell lines (highlighted in red dots). The Pearson correlation coefficient (R) and the statistical significance of the correlation (P) were determined via a correlation test implemented in R software.

Back to article page